AbstractsThe mathematical basis for the Ruedenberg's and Mulliken's approximations is given in a general framework.Les bases mathCmatiques des approximations de Ruedenberg et de Mulliken sont prCsenttes dans un cadre g6nCral. Die mathematische Basis de Ruedenberg'schen und Mulliken'schen Naherungen wird in einem allgemeinen Rahmen gegeben.Consider an electronic system defined by a countable set of subsystems (atoms, molecular fragments, molecules, etc.) with associated sets of basis functions Sr = {C#JL ; p E I}. If I and J are two different subsystems, one can write the set Sr in terms of linear combinations of the elements of S J :The {a::] are a set of appropriate coefficients, which can be defined through the equation where are the elements of the system's metric matrix.submatrices, one can construct a hypermatrix With the overlap elements partitioned between intra-and intersubsystems

No abstract

No abstract

The effectiveness and duration of the anti-anginal action of two sustained-release preparations, molsidomine (8 mg) and isosorbide dinitrate (20 mg), were assessed by means of serial exercise tests in 12 patients with angina of effort. The tests, which were limited by the symptoms, were carried out on three consecutive days using the Bruce protocol. Each patient was tested four times each day: the first test was performed before treatment and the others were carried out 1, 4 and 8 h after administration of the drug or placebo. One hour after administration of molsidomine, the appearance of signs of ischaemia in the ECG were considerably delayed and they were reduced in magnitude. Furthermore, the length of time during which the patients were free of angina increased. After 4 h both drugs significantly delayed the onset of angina and depression of the ST segment by 1 mm. The conclusion is that at the doses used both drugs prolong the length of time in which there is no angina, but that they have no significant effect at 8 h.

The results of treatment of neurotic disorders with single or divided daily doses of the anxiolytic drug clobazam have been compared. The trial was performed in two groups, each of 57 patients, paired according to age, sex, diagnosis, severity of initial disorder, and total daily dose. The 114 subjects formed a random subgroup from a total of 1369 patients taking part in a postmarketing surveillance trial of clobazam. In view of the changes in the overall severity of the symptoms, in "persistent anxiety" and "anxiety crises", in "sleep disorders", the global clinical impression and the tolerance, it is concluded that clobazam is a useful drug in the treatment of anxiety, and that single or divided daily dosage schedules produce similar results.